Deepak Kumar Jha
Deepak Kumar Jha has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Mehdi Fathima
Department of Pharmacology, Karnataka College of Pharmacy, Bangalore, Karnataka, India
3 shared publicationsSaroj Kumar Sah
Department of Pharmacology, Karnataka College of Pharmacy, Bangalore, Karnataka, India
3 shared publications- Mary Brenda Ogwang
Department of Pharmacology, Karnataka College of Pharmacy, Bengaluru, India
2 shared publications Soham Bhattacharjee
Department of Pharmacology, Karnataka College of Pharmacy, Bangalore, Karnataka, India
2 shared publications- Y. Bharathi
Karnataka College of Pharmacy
2 shared publications Abdullah Ali Mohammed Ali
Department of Pharmacology, Karnataka College of Pharmacy, Bangalore, Karnataka, India
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 17 (1) , 215-223
Assessment of Safety and Efficacy of Cellular Therapy on Foot Ulcer in Diabetic Animal: A Preclinical Investigation
Aim and Objectives: Around 20% of diabetic patients are at increased risk of chronic foot ulcers. Current treatments mainly focus on glycemic control and supportive care, with limited effectiveness. Mononuclear Cell (MNC) therapy, containing hematopoietic, mesenchymal, and progenitor cells, is emerging as a novel and effective regenerative approach for Diabetic Foot Ulcers (DFU). The objective of the study is to evaluate the safety profile and healing efficacy of MNC-based therapy in a diabetic rat model of non-healing wounds. Materials and Methods: 36- male Wistar rats (150–200 g) were randomized into different groups (n=6): Normal Healthy Control, Diabetic Control (STZ + Ulcer control), Mupirocin, Insulin + Mupirocin, MNCs (~10 × 10⁶ cells), and MNCs (~10 × 10⁶ cells) + Insulin. A diabetic model was induced in experimental rats using STZ (50 mg/kg, i.p.). From each diabetic rat, 1.5 mL of blood was collected to isolate MNCs, which were resuspended in 0.5 mL of autologous plasma and injected once at the ulcer site. Insulin groups received 4 IU/day (s.c.). The end points of our study evaluated various parameters, including wound closure, serum insulin, blood glucose, lymphocyte/NLR profiles, inflammatory markers (TNF-α, IL-6), and histology. Results: The combination of insulin and MNC-based therapy was well tolerated and resulted in a significant reduction in hyperglycemia, reduced inflammation, and enhanced the wound closure rate. This combinatorial approach facilitated tissue homeostasis and aided in the remodeling of cells for functional restoration. MNC therapy combined with insulin resulted in a marked glycemic reduction (pppConclusion: MNC-based therapy can serve as a promising candidate for treating diabetic patients with non-healing ulcers.
- 16 October 2026
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 17 (1) , 215-223
Open AccessAssessment of Safety and Efficacy of Cellular Therapy on Foot Ulcer in Diabetic Animal: A Preclinical Investigation
Aim and Objectives: Around 20% of diabetic patients are at increased risk of chronic foot ulcers. Current treatments mainly focus on glycemic control and supportive care, with limited effectiveness. Mononuclear Cell (MNC) therapy, containing hematopoietic, mesenchymal, and progenitor cells, is emerging as a novel and effective regenerative approach for Diabetic Foot Ulcers (DFU). The objective of the study is to evaluate the safety profile and healing efficacy of MNC-based therapy in a diabetic rat model of non-healing wounds. Materials and Methods: 36- male Wistar rats (150–200 g) were randomized into different groups (n=6): Normal Healthy Control, Diabetic Control (STZ + Ulcer control), Mupirocin, Insulin + Mupirocin, MNCs (~10 × 10⁶ cells), and MNCs (~10 × 10⁶ cells) + Insulin. A diabetic model was induced in experimental rats using STZ (50 mg/kg, i.p.). From each diabetic rat, 1.5 mL of blood was collected to isolate MNCs, which were resuspended in 0.5 mL of autologous plasma and injected once at the ulcer site. Insulin groups received 4 IU/day (s.c.). The end points of our study evaluated various parameters, including wound closure, serum insulin, blood glucose, lymphocyte/NLR profiles, inflammatory markers (TNF-α, IL-6), and histology. Results: The combination of insulin and MNC-based therapy was well tolerated and resulted in a significant reduction in hyperglycemia, reduced inflammation, and enhanced the wound closure rate. This combinatorial approach facilitated tissue homeostasis and aided in the remodeling of cells for functional restoration. MNC therapy combined with insulin resulted in a marked glycemic reduction (pppConclusion: MNC-based therapy can serve as a promising candidate for treating diabetic patients with non-healing ulcers.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 105-119
Global Cancer Trends: The Rise of a Global Health Crisis and Innovative Pathways to Solutions
Background: Cancer is a major global health crisis. WHO projections indicate a 60% rise in cancer cases by 2040 due to lifestyle changes and an ageing population, placing a significant burden on healthcare systems, economies, and families, particularly in developing countries with limited access to medical resources.Objective: This paper aims to provide a comprehensive understanding of the current landscape and potential pathways to reducing cancer mortality and improving patient outcomes worldwide.Materials and Methods: For this review, we synthesised peer-reviewed literature from indexed journals such as Scopus, PubMed, Web of Science, Elsevier, and ScienceDirect.Results: Key risk factors, including smoking, poor diet, environmental pollution, and physical inactivity, further drive the increasing prevalence of cancer. Despite these challenges, advancements in cancer research and global initiatives provide hope. WHO-led programmes, such as the Global Initiative for Cancer Care and the Cervical Cancer Elimination Strategy, alongside collaborative efforts like the Cancer Moonshot Initiative and Medicines Patent Pool, are improving cancer prevention, screening, and treatment worldwide. Innovations in precision oncology, including next-generation sequencing, liquid biopsies, nanotechnology-based drug delivery, and gene-editing technologies like CRISPR-Cas9 and CAR-T cell therapy, are transforming cancer diagnosis and treatment. While these advancements enhance patient outcomes, challenges such as off-target effects, ethical concerns, and gene delivery limitations must be addressed for broader clinical implementation.Conclusion: A comprehensive, multi-pronged approach combining scientific advancements, equitable healthcare access, and preventive strategies is crucial to mitigating the global cancer burden.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 105-119
Global Cancer Trends: The Rise of a Global Health Crisis and Innovative Pathways to Solutions
Background: Cancer is a major global health crisis. WHO projections indicate a 60% rise in cancer cases by 2040 due to lifestyle changes and an ageing population, placing a significant burden on healthcare systems, economies, and families, particularly in developing countries with limited access to medical resources.Objective: This paper aims to provide a comprehensive understanding of the current landscape and potential pathways to reducing cancer mortality and improving patient outcomes worldwide.Materials and Methods: For this review, we synthesised peer-reviewed literature from indexed journals such as Scopus, PubMed, Web of Science, Elsevier, and ScienceDirect.Results: Key risk factors, including smoking, poor diet, environmental pollution, and physical inactivity, further drive the increasing prevalence of cancer. Despite these challenges, advancements in cancer research and global initiatives provide hope. WHO-led programmes, such as the Global Initiative for Cancer Care and the Cervical Cancer Elimination Strategy, alongside collaborative efforts like the Cancer Moonshot Initiative and Medicines Patent Pool, are improving cancer prevention, screening, and treatment worldwide. Innovations in precision oncology, including next-generation sequencing, liquid biopsies, nanotechnology-based drug delivery, and gene-editing technologies like CRISPR-Cas9 and CAR-T cell therapy, are transforming cancer diagnosis and treatment. While these advancements enhance patient outcomes, challenges such as off-target effects, ethical concerns, and gene delivery limitations must be addressed for broader clinical implementation.Conclusion: A comprehensive, multi-pronged approach combining scientific advancements, equitable healthcare access, and preventive strategies is crucial to mitigating the global cancer burden.
- 22 April 2026
- Published by Sciencedomain International in Current Journal of Applied Science and Technology
- Vol. 45 (5) , 46-62
Neurodegeneration in Alzheimer’s Disease: Integrating Mechanism with Translational Therapeutic Strategies
Alzheimer disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia in the world, which has a gradual deterioration of memory, thinking and autonomy. The AD pathogenesis is a multifaceted and intricate interaction between molecular/cellular processes like amyloid-ß (Aß) aggregation, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, vascular changes, and genetic predisposing factors (APOE 4 allele). The amyloid cascade proposal suggests that when there is an anomaly in the handling of amyloid precursor protein, it will cause aggregation of Aß, which will culminate into the development of toxic oligomers and as well as extracellular plaques, and the eventual destruction of neurons. Tau pathology is also associated with a further role in neurodegeneration by causing intracellular neurofibrillary tangles and impairment of transport via axons. The studies on biomarkers obtained in recent years, such as cerebrospinal fluid biomarkers, plasma phosphorylated tau, and neuroimaging, such as structural MRI, have greatly augmented the exquisite rooting of the disease by detecting and classifying in its initial phases using AT(N) biomarker framework. Symbolic treatment has changed to disease-modifying treatment designed to inhibit the cholinergic system, glutamatergic system, anti-amyloid monoclonal antibodies, anti-tau therapy, and neuroinflammatory and metabolic dysfunction modulators. New technologies such as gene-editing, stem cell-therapy, exosome-therapy, digital-neuromodulation technologies etc also add to the translational therapeutic landscape. Moreover, multidomain lifestyle intervention, cognitive engagement, and any preventive approach to vascular risk management can be vital to eliminate the risk and development of diseases. Irrespective of these developments, there are still major challenges in translational research, such as heterogeneity of diseases, evaluation limitations of preclinical models, and inability to intervene clinically promptly. Precision medicine methods with multimodal biomarkers, early-stage diagnostics, and combination therapy should be considered in the future research to enhance the clinical outcomes and decrease the worldwide Alzheimer disease burden.
- 22 April 2026
- Published by Sciencedomain International in Current Journal of Applied Science and Technology
- Vol. 45 (5) , 46-62
Neurodegeneration in Alzheimer’s Disease: Integrating Mechanism with Translational Therapeutic Strategies
Alzheimer disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia in the world, which has a gradual deterioration of memory, thinking and autonomy. The AD pathogenesis is a multifaceted and intricate interaction between molecular/cellular processes like amyloid-ß (Aß) aggregation, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, vascular changes, and genetic predisposing factors (APOE 4 allele). The amyloid cascade proposal suggests that when there is an anomaly in the handling of amyloid precursor protein, it will cause aggregation of Aß, which will culminate into the development of toxic oligomers and as well as extracellular plaques, and the eventual destruction of neurons. Tau pathology is also associated with a further role in neurodegeneration by causing intracellular neurofibrillary tangles and impairment of transport via axons. The studies on biomarkers obtained in recent years, such as cerebrospinal fluid biomarkers, plasma phosphorylated tau, and neuroimaging, such as structural MRI, have greatly augmented the exquisite rooting of the disease by detecting and classifying in its initial phases using AT(N) biomarker framework. Symbolic treatment has changed to disease-modifying treatment designed to inhibit the cholinergic system, glutamatergic system, anti-amyloid monoclonal antibodies, anti-tau therapy, and neuroinflammatory and metabolic dysfunction modulators. New technologies such as gene-editing, stem cell-therapy, exosome-therapy, digital-neuromodulation technologies etc also add to the translational therapeutic landscape. Moreover, multidomain lifestyle intervention, cognitive engagement, and any preventive approach to vascular risk management can be vital to eliminate the risk and development of diseases. Irrespective of these developments, there are still major challenges in translational research, such as heterogeneity of diseases, evaluation limitations of preclinical models, and inability to intervene clinically promptly. Precision medicine methods with multimodal biomarkers, early-stage diagnostics, and combination therapy should be considered in the future research to enhance the clinical outcomes and decrease the worldwide Alzheimer disease burden.
- 7 April 2026
- Published by Sciencedomain International in Current Journal of Applied Science and Technology
- Vol. 45 (4) , 14-33
Regenerative and Cellular Therapies in Arthritis: Mechanisms, Clinical Evidence and Translational Challenges
Background: Arthritis, and especially osteoarthritis and rheumatoid arthritis, contribute to chronic pain and disability and diminished quality of life on a global scale. Treatment approaches that are used currently seem to be based mainly on treating the symptoms without repairing the structures or modifying the disease, making regenerative approaches important. Aim: This review will synthesize and critically assess regenerative and cellular therapies in arthritis, their mechanisms, clinical trials, limitations, and potential to be used in translation. Materials and Methods: A comprehensive narrative literature review was conducted using electronic databases, including PubMed, Scopus, and Web of Science. The review comprised preclinical studies, randomized controlled trials, and clinical studies focusing on cell-based therapies, biological adjuncts, tissue engineering strategies, and gene therapy approaches in arthritis. Relevant articles published between 2010 and 2026 were identified using keywords such as “arthritis,” “mesenchymal stem cells,” “regenerative therapy,” “platelet-rich plasma,” and “extracellular vesicles,” with Boolean operators applied to refine the search. Studies were selected based on relevance, methodological quality, and availability in English, while non-relevant and non-peer-reviewed articles were excluded. Findings: The therapies derived from mesenchymal stem cells, autologous chondrocyte implantation, and induced pluripotent stem cells show promise in terms of cartilage regeneration and immunomodulation. The cell-free strategies, such as platelet-rich plasma, as well as extracellular vesicles, have promising anti-inflammatory and regenerative properties. Better therapeutic outcomes are achieved through the use of biomaterial scaffolds, tissue engineering, and gene therapy. Nevertheless, the clinical evidence is still divided, and some of the shortcomings comprise cell source variations, the absence of standardized protocols, nonuniform outcome measures, and the paucity of long-term data. Conclusion: Regenerative therapies are a promising transition to disease-modifying therapy in arthritis. Nonetheless, successful clinical translation depends on them, and there is a need for standardization of cell characterization, harmonization of clinical endpoints, scalability of production, and effective long-term clinical trials. The development of multimodal and combination interventions can also enhance the efficiency of the therapy process to further develop and become a means of its transfer to clinical practice.
- 7 April 2026
- Published by Sciencedomain International in Current Journal of Applied Science and Technology
- Vol. 45 (4) , 14-33
Regenerative and Cellular Therapies in Arthritis: Mechanisms, Clinical Evidence and Translational Challenges
Background: Arthritis, and especially osteoarthritis and rheumatoid arthritis, contribute to chronic pain and disability and diminished quality of life on a global scale. Treatment approaches that are used currently seem to be based mainly on treating the symptoms without repairing the structures or modifying the disease, making regenerative approaches important. Aim: This review will synthesize and critically assess regenerative and cellular therapies in arthritis, their mechanisms, clinical trials, limitations, and potential to be used in translation. Materials and Methods: A comprehensive narrative literature review was conducted using electronic databases, including PubMed, Scopus, and Web of Science. The review comprised preclinical studies, randomized controlled trials, and clinical studies focusing on cell-based therapies, biological adjuncts, tissue engineering strategies, and gene therapy approaches in arthritis. Relevant articles published between 2010 and 2026 were identified using keywords such as “arthritis,” “mesenchymal stem cells,” “regenerative therapy,” “platelet-rich plasma,” and “extracellular vesicles,” with Boolean operators applied to refine the search. Studies were selected based on relevance, methodological quality, and availability in English, while non-relevant and non-peer-reviewed articles were excluded. Findings: The therapies derived from mesenchymal stem cells, autologous chondrocyte implantation, and induced pluripotent stem cells show promise in terms of cartilage regeneration and immunomodulation. The cell-free strategies, such as platelet-rich plasma, as well as extracellular vesicles, have promising anti-inflammatory and regenerative properties. Better therapeutic outcomes are achieved through the use of biomaterial scaffolds, tissue engineering, and gene therapy. Nevertheless, the clinical evidence is still divided, and some of the shortcomings comprise cell source variations, the absence of standardized protocols, nonuniform outcome measures, and the paucity of long-term data. Conclusion: Regenerative therapies are a promising transition to disease-modifying therapy in arthritis. Nonetheless, successful clinical translation depends on them, and there is a need for standardization of cell characterization, harmonization of clinical endpoints, scalability of production, and effective long-term clinical trials. The development of multimodal and combination interventions can also enhance the efficiency of the therapy process to further develop and become a means of its transfer to clinical practice.
- Open Access
- 7 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- p. 1-15
EXPLORING THE ROLE OF UMBILICAL CORD AND CORD BLOOD IN REGENERATIVE MEDICINE
UC/umbilical cord blood (UCB) has become an important option as sources of various types of stem cells to treat chronic diseases of various origins (blood disorders, autoimmune disorders, neurodegenerative diseases, cardiac diseases, diabetes, cancer, gastric and liver diseases, etc.). This is because these stem cells have demonstrated the potential to differentiate into mature cells and also to activate the endogenous progenitor cells to regenerate the tissue. In addition, a subpopulation of stem cells known as Mesenchymal Stem cells (MSCs) has the unique ability to modulate the immune cell response through cell-to-cell interactions and/or by the abundant production of various growth factors, cytokines, and extracellular vesicles. UC and UCB-derived stem cells have emerged as superior alternatives due to their ethical acceptability, ease of procurement, and robust regenerative potential. Many clinical trials are being run using MSCs for the treatment of various disorders. Most importantly, the cells derived from these sources are readily available and present no serious ethical challenges, thereby making them an important therapeutic candidate in clinical settings. This review uniquely synthesizes the mechanistic pathways of UCB and Umbilical Cord (UC) across different major therapeutic areas and critically appraises the translational challenges from a clinical perspective. Moreover, we have also provided insights on the use of UCB/UC and its derivatives as vehicles for the delivery of therapeutic agents to the target tissue. These findings underscore the potential of UCB and UC not only as standalone treatments but also as innovative platforms for enhancing the efficacy of existing therapies. In addition, this review also highlighted the preclinical and clinical results that have been obtained using UCB and UC in various fields, as well as the challenges and regulatory limitations of those products in clinical settings. Future research should focus on overcoming regulatory hurdles and optimizing delivery systems to maximize patient outcomes.
- 7 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- p. 1-15
Open AccessEXPLORING THE ROLE OF UMBILICAL CORD AND CORD BLOOD IN REGENERATIVE MEDICINE
UC/umbilical cord blood (UCB) has become an important option as sources of various types of stem cells to treat chronic diseases of various origins (blood disorders, autoimmune disorders, neurodegenerative diseases, cardiac diseases, diabetes, cancer, gastric and liver diseases, etc.). This is because these stem cells have demonstrated the potential to differentiate into mature cells and also to activate the endogenous progenitor cells to regenerate the tissue. In addition, a subpopulation of stem cells known as Mesenchymal Stem cells (MSCs) has the unique ability to modulate the immune cell response through cell-to-cell interactions and/or by the abundant production of various growth factors, cytokines, and extracellular vesicles. UC and UCB-derived stem cells have emerged as superior alternatives due to their ethical acceptability, ease of procurement, and robust regenerative potential. Many clinical trials are being run using MSCs for the treatment of various disorders. Most importantly, the cells derived from these sources are readily available and present no serious ethical challenges, thereby making them an important therapeutic candidate in clinical settings. This review uniquely synthesizes the mechanistic pathways of UCB and Umbilical Cord (UC) across different major therapeutic areas and critically appraises the translational challenges from a clinical perspective. Moreover, we have also provided insights on the use of UCB/UC and its derivatives as vehicles for the delivery of therapeutic agents to the target tissue. These findings underscore the potential of UCB and UC not only as standalone treatments but also as innovative platforms for enhancing the efficacy of existing therapies. In addition, this review also highlighted the preclinical and clinical results that have been obtained using UCB and UC in various fields, as well as the challenges and regulatory limitations of those products in clinical settings. Future research should focus on overcoming regulatory hurdles and optimizing delivery systems to maximize patient outcomes.
- Open Access
- 30 September 2025
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 452-460
Comparative Study of Neuroprotective Activity of Mucuna pruriens and Withania somnifera Against Haloperidol Induced Parkinson’s Disease in animal model
Parkinson’s Disease (PD), initially was a challenging Neurodegenerative Disorder (ND) to treat and manage, but translational research bridged the gap to its risk factors, pathophysiology, diagnosis, treatment and management. Research is more focused on neuroprotection with the purpose of preventing neuronal loss reaching more than 60% exhibiting symptomatic PD, and neuro-rescue to restore functionality to partly damaged cells. Thus, this comparative study investigated Mucuna pruriens and Withania somnifera’s neuroprotective properties, as this may help to uncover and establish similar pathways in their mechanisms of action, and/or differences to determine if synergism may be possible. The administration of haloperidol resulted in significant motor damage, oxidative stress, and also high pro-inflammatory cytokines. M. pruriens and W. somnifera extract pre-treatment showed dose-dependent beneficial effects on behavior parameters, enhancing GSH levels and decreasing LPO levels, and remarkably reduced the levels of inflammatory cytokines. These results were corroborated by histopathological analysis of brain tissues, which indicated well-preserved brain neuronal integrity and limited evidence of neurodegeneration. Moreover, the in vitro MTT test using Neuro-2a cells showed that both extracts were able to support high cell viability; it is implied that the extracts may possess cytoprotective potentials on the cellular level. The experiment shows that Mucuna pruriens and Withania somnifera have substantial neuroprotective and anti-inflammatory effects on haloperidol-induced neurotoxicity, W. somnifera having a better overall outcome as compared to M. pruriens.
- 30 September 2025
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 452-460
Open AccessComparative Study of Neuroprotective Activity of Mucuna pruriens and Withania somnifera Against Haloperidol Induced Parkinson’s Disease in animal model
Parkinson’s Disease (PD), initially was a challenging Neurodegenerative Disorder (ND) to treat and manage, but translational research bridged the gap to its risk factors, pathophysiology, diagnosis, treatment and management. Research is more focused on neuroprotection with the purpose of preventing neuronal loss reaching more than 60% exhibiting symptomatic PD, and neuro-rescue to restore functionality to partly damaged cells. Thus, this comparative study investigated Mucuna pruriens and Withania somnifera’s neuroprotective properties, as this may help to uncover and establish similar pathways in their mechanisms of action, and/or differences to determine if synergism may be possible. The administration of haloperidol resulted in significant motor damage, oxidative stress, and also high pro-inflammatory cytokines. M. pruriens and W. somnifera extract pre-treatment showed dose-dependent beneficial effects on behavior parameters, enhancing GSH levels and decreasing LPO levels, and remarkably reduced the levels of inflammatory cytokines. These results were corroborated by histopathological analysis of brain tissues, which indicated well-preserved brain neuronal integrity and limited evidence of neurodegeneration. Moreover, the in vitro MTT test using Neuro-2a cells showed that both extracts were able to support high cell viability; it is implied that the extracts may possess cytoprotective potentials on the cellular level. The experiment shows that Mucuna pruriens and Withania somnifera have substantial neuroprotective and anti-inflammatory effects on haloperidol-induced neurotoxicity, W. somnifera having a better overall outcome as compared to M. pruriens.
- Open Access
- 30 September 2025
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 461-471
Chemopreventive Potential of Celastrus paniculatus Seeds Extract in DMBA Synergistic with Croton Oil-Induced Skin Carcinogenesis in Swiss Albino Murine Model
As one of the leading and fatal public health problems, skin cancer’s progression is highly influenced by chronic inflammatory reactions and oxidative stress, accompanied by DNA mutation. Need for multi-option, plant-based alternatives, as first mentioned by Michael Sporn in 1976, offering chemoprevention to prevent initiation or inhibit tumor promotion and progression, and/or chemoprotection by use of plant-derived immunostimulants with the intention of immune system stimulation to either slow down or stop cancer evolution has been established as acceptable standard treatment is costly and has severe side effects. The present study was designed to assess the chemopreventive effect of Celastrus paniculatus seeds against DMBA–induced skin carcinogenesis in Swiss albino mice followed by croton oil administration. Parameters assessed included tumor incidence, yield, size, average latent period, hematological subsets, oxidative stress markers (LPO, CAT), inflammatory cytokines (TNF-α, IL-6), and histopathology. The disease control group (DMBA + croton oil application) showed 100% tumor incidence, high tumor yield, large papillomas (>8 mm), elevated LPO, reduced CAT, increased TNF-α, and IL-6 levels. The treatment groups showed promising results in contrast to the respective control groups. The oral + topical 400 mg/kg group showed the most pronounced protection, with tumor incidence reduced to 13.4%, tumor yield 0.33/mouse, the smallest papillomas (<2 mm), near-normal skin in histological assessments, restored CAT, reduced LPO levels, and normalized systemic inflammatory marker levels. C. paniculatus methanolic seed extract demonstrated dose- and route-dependent chemopreventive effects, with oral + topical 400 mg/kg showing the most promising effects, suggesting potential as well as a safer alternative adjuvant therapy along with the standard care in skin cancer prevention.
- 30 September 2025
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 461-471
Open AccessChemopreventive Potential of Celastrus paniculatus Seeds Extract in DMBA Synergistic with Croton Oil-Induced Skin Carcinogenesis in Swiss Albino Murine Model
As one of the leading and fatal public health problems, skin cancer’s progression is highly influenced by chronic inflammatory reactions and oxidative stress, accompanied by DNA mutation. Need for multi-option, plant-based alternatives, as first mentioned by Michael Sporn in 1976, offering chemoprevention to prevent initiation or inhibit tumor promotion and progression, and/or chemoprotection by use of plant-derived immunostimulants with the intention of immune system stimulation to either slow down or stop cancer evolution has been established as acceptable standard treatment is costly and has severe side effects. The present study was designed to assess the chemopreventive effect of Celastrus paniculatus seeds against DMBA–induced skin carcinogenesis in Swiss albino mice followed by croton oil administration. Parameters assessed included tumor incidence, yield, size, average latent period, hematological subsets, oxidative stress markers (LPO, CAT), inflammatory cytokines (TNF-α, IL-6), and histopathology. The disease control group (DMBA + croton oil application) showed 100% tumor incidence, high tumor yield, large papillomas (>8 mm), elevated LPO, reduced CAT, increased TNF-α, and IL-6 levels. The treatment groups showed promising results in contrast to the respective control groups. The oral + topical 400 mg/kg group showed the most pronounced protection, with tumor incidence reduced to 13.4%, tumor yield 0.33/mouse, the smallest papillomas (<2 mm), near-normal skin in histological assessments, restored CAT, reduced LPO levels, and normalized systemic inflammatory marker levels. C. paniculatus methanolic seed extract demonstrated dose- and route-dependent chemopreventive effects, with oral + topical 400 mg/kg showing the most promising effects, suggesting potential as well as a safer alternative adjuvant therapy along with the standard care in skin cancer prevention.
- Open Access
- 6 September 2025
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 17 (3) , 520-531
Understanding the Post-COVID Cardiovascular Impact: Manifestations, Prevalence, and Clinical Evaluation
There is growing evidence highlighting a significant risk of cardiovascular complications in patients recovering from COVID-19, particularly among those experiencing long COVID or persistent post-acute symptoms. Numerous studies have shown that COVID-19 can trigger or exacerbate cardiovascular conditions such as myocarditis, arrhythmias, thromboembolic events, and heart failure, even in individuals without a prior history of cardiovascular disease. The objective of this review is to evaluate the prevalence and risk of cardiovascular complications following COVID-19 infection. By synthesizing current research findings, this paper aims to provide a comprehensive understanding of how COVID-19, especially in its long-term manifestations, contributes to increased cardiovascular risk. A systematic literature search was conducted using PubMed, Scopus, and Google Scholar to identify relevant studies. Key findings indicate an increase in cardiovascular mortality across countries during 2020, with COVID-19 significantly contributing to the incidence of myocarditis, arrhythmias, heart failure, and thrombotic events-particularly among older adults and those with pre-existing conditions. Long COVID is often associated with persistent cardiac manifestations, driven by inflammation, endothelial dysfunction, and hypercoagulability. The findings highlight the importance of managing chronic conditions and establishing specialized clinics for ongoing care. Routine cardiovascular screening, comorbidity management, and vaccination are essential components in preventing and mitigating cardiovascular complications in post-COVID patients.
- 6 September 2025
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 17 (3) , 520-531
Open AccessUnderstanding the Post-COVID Cardiovascular Impact: Manifestations, Prevalence, and Clinical Evaluation
There is growing evidence highlighting a significant risk of cardiovascular complications in patients recovering from COVID-19, particularly among those experiencing long COVID or persistent post-acute symptoms. Numerous studies have shown that COVID-19 can trigger or exacerbate cardiovascular conditions such as myocarditis, arrhythmias, thromboembolic events, and heart failure, even in individuals without a prior history of cardiovascular disease. The objective of this review is to evaluate the prevalence and risk of cardiovascular complications following COVID-19 infection. By synthesizing current research findings, this paper aims to provide a comprehensive understanding of how COVID-19, especially in its long-term manifestations, contributes to increased cardiovascular risk. A systematic literature search was conducted using PubMed, Scopus, and Google Scholar to identify relevant studies. Key findings indicate an increase in cardiovascular mortality across countries during 2020, with COVID-19 significantly contributing to the incidence of myocarditis, arrhythmias, heart failure, and thrombotic events-particularly among older adults and those with pre-existing conditions. Long COVID is often associated with persistent cardiac manifestations, driven by inflammation, endothelial dysfunction, and hypercoagulability. The findings highlight the importance of managing chronic conditions and establishing specialized clinics for ongoing care. Routine cardiovascular screening, comorbidity management, and vaccination are essential components in preventing and mitigating cardiovascular complications in post-COVID patients.
- 5 September 2025
- Published by IGI Global Scientific Publishing
- p. 173-220
Bioprocess Optimization Strategies
With the increasing global demand for biopharmaceuticals and industrial biologics, optimizing biomanufacturing processes become imperative. The optimization of bioprocesses aims to maximize the efficiency and yield in biomanufacturing while maintaining cost-effectiveness. This chapter discusses the key strategies employed for bioprocess optimization and scale-up for the efficient production of biological products. It also discusses the importance of bioreactor configuration refinements, dynamic media optimization, process parameter refinement and real-time monitoring via advanced PAT. The integration of AI and ML in predictive modelling, efficiency enhancement and minimizing operational risks are also presented. Furthermore, the transition from batch to continuous manufacturing and the implementation of QbD as key drivers of efficiency and consistency are emphasized. Optimizing downstream processing are equally crucial to enable higher product recovery. Finally, addressing key bottlenecks such as scale-up and regulatory constraints are also reviewed.
- 5 September 2025
- Published by IGI Global Scientific Publishing
- p. 173-220
Bioprocess Optimization Strategies
With the increasing global demand for biopharmaceuticals and industrial biologics, optimizing biomanufacturing processes become imperative. The optimization of bioprocesses aims to maximize the efficiency and yield in biomanufacturing while maintaining cost-effectiveness. This chapter discusses the key strategies employed for bioprocess optimization and scale-up for the efficient production of biological products. It also discusses the importance of bioreactor configuration refinements, dynamic media optimization, process parameter refinement and real-time monitoring via advanced PAT. The integration of AI and ML in predictive modelling, efficiency enhancement and minimizing operational risks are also presented. Furthermore, the transition from batch to continuous manufacturing and the implementation of QbD as key drivers of efficiency and consistency are emphasized. Optimizing downstream processing are equally crucial to enable higher product recovery. Finally, addressing key bottlenecks such as scale-up and regulatory constraints are also reviewed.
- 8 August 2025
- Published by Sciencedomain International in Journal of Advances in Medical and Pharmaceutical Sciences
- Vol. 27 (8) , 1-22
An Integrated Review of Parkinson’s Disease: Etiology, Differential Diagnosis, Biomarkers, Emerging Therapeutic Approaches, and Translational Models
Aims and Objectives: This review aims to provide a comprehensive overview of risk factors, biomarkers, pathophysiology, and synthesis of experimental models of Parkinson’s Disease (PD), with an emphasis on their mechanisms and translational models. Materials and Methods: A narrative review methodology was employed, involving an extensive literature search using databases such as PubMed, Scopus, and Web of Science. Peer-reviewed articles published up to 2025 were included. Results: Pre-clinical and clinical research has provided evidence that has enabled the decoding of Parkinson’s Disease (PD) and a breakthrough in its management/treatment. Despite the underlying mechanism not being fully understood, we now have a better interpretation of its sophisticated nature. This article highlights risk factors, some of which may be considered normal ageing but need to be addressed; diagnostic biomarkers, some of which help differentiate PD from Parkinsonism, others, less invasive, identify at-risk individuals, and neuroinflammation. This article also highlights the different pathophysiology, which also helps to emphasis the heterogeneous nature. It highlights the diverse experimental PD models because no one model fully represents PD and the research work that has been reported. This may help one to understand “the missing pieces of the puzzle”, with a note that the precision medicine framework may play a crucial role in benefiting and transforming the lives of people living with Parkinson’s Disease. Conclusions: There is no single model that fully recapitulates all aspects of PD. However, the strategic selection or combination of models can provide valuable insights into disease mechanisms and treatment efficacy. Future directions should focus on refining models that mimic progressive and heterogeneous disease features, integrating multi-omics approaches, and validating biomarkers for clinical translation. A precision medicine framework may ultimately transform PD management by linking experimental data to patient-specific therapeutic strategies.
- 8 August 2025
- Published by Sciencedomain International in Journal of Advances in Medical and Pharmaceutical Sciences
- Vol. 27 (8) , 1-22
An Integrated Review of Parkinson’s Disease: Etiology, Differential Diagnosis, Biomarkers, Emerging Therapeutic Approaches, and Translational Models
Aims and Objectives: This review aims to provide a comprehensive overview of risk factors, biomarkers, pathophysiology, and synthesis of experimental models of Parkinson’s Disease (PD), with an emphasis on their mechanisms and translational models. Materials and Methods: A narrative review methodology was employed, involving an extensive literature search using databases such as PubMed, Scopus, and Web of Science. Peer-reviewed articles published up to 2025 were included. Results: Pre-clinical and clinical research has provided evidence that has enabled the decoding of Parkinson’s Disease (PD) and a breakthrough in its management/treatment. Despite the underlying mechanism not being fully understood, we now have a better interpretation of its sophisticated nature. This article highlights risk factors, some of which may be considered normal ageing but need to be addressed; diagnostic biomarkers, some of which help differentiate PD from Parkinsonism, others, less invasive, identify at-risk individuals, and neuroinflammation. This article also highlights the different pathophysiology, which also helps to emphasis the heterogeneous nature. It highlights the diverse experimental PD models because no one model fully represents PD and the research work that has been reported. This may help one to understand “the missing pieces of the puzzle”, with a note that the precision medicine framework may play a crucial role in benefiting and transforming the lives of people living with Parkinson’s Disease. Conclusions: There is no single model that fully recapitulates all aspects of PD. However, the strategic selection or combination of models can provide valuable insights into disease mechanisms and treatment efficacy. Future directions should focus on refining models that mimic progressive and heterogeneous disease features, integrating multi-omics approaches, and validating biomarkers for clinical translation. A precision medicine framework may ultimately transform PD management by linking experimental data to patient-specific therapeutic strategies.